Highlights of This Issue  567

REVIEW

569  Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
Enrique Grande, Maria-Victoria Bolos, and Edurne Arriola

THERAPEUTIC DISCOVERY

580  GPR54 Is a Target for Suppression of Metastasis in Endometrial Cancer
Hyun Sook Kang, Tsukasa Baba, Masaki Mandai, Noriomi Matsumura, Junzo Hamanishi, Budiman Kharma, Eiji Kondoh, Yumiko Yoshioka, Shinya Oishi, Nobutaka Fujii, Susan K. Murphy, and Ikuo Konishi

591  Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Frances Shanahan, Nicole Davis, Lorena Taricani, Derek Wiswell, Wolfgang Seghezzi, Ervin Penafior, Bhagyashree Bhagwat, Wei Wang, Danling Gu, Yunsheng Hsieh, Suining Lee, Ming Liu, and David Parry

603  Targeted Delivery of an Antibody–Mutant Human Endostatin Fusion Protein Results in Enhanced Antitumor Efficacy
Seung-Uon Shin, Hyun-Mi Cho, Jaime Merchan, Jin Zhang, Krisztina Kovacs, Yawu Jing, Sundaram Ramakrishnan, and Joseph D. Rosenblatt

615  Novel Functions for mda-7/IL-24 and IL-24 delE5: Regulation of Differentiation of Acute Myeloid Leukemic Cells
Bin-Xia Yang, Yong-Juan Duan, Cheng-Ya Dong, Fang Zhang, Wei-Feng Gao, Xue-Ying Cui, Yong-Min Lin, and Xiao-Tong Ma

PRECLINICAL DEVELOPMENT

626  Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase
May Khanna, Bhadrani Chelladurai, Aruna Gavini, Liwei Li, Minghai Shao, David Courtney, John J. Turchi, Daniela Matei, and Samy Meroueh

Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer
Yuh-Pyng Sher, Shih-Jen Liu, Chun-Mien Chang, Shu-Pei Lien, Chien-Hua Chen, Zhenbo Han, Long-Yuan Li, Jin-Shing Chen, Cheng-Wen Wu, and Mien-Chie Hung

637  Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and In vivo Models for Intestinal and Prostate Cancer
Holly Symolon, Anatoliy Bushnev, Qiong Peng, Harsha Ramaraju, Suzanne G. Mays, Jeremy C. Allegood, Sarah T. Pruett, M. Cameron Sullards, Dirk L. Dillehay, Dennis C. Liotta, and Alfred H. Merrill, Jr.

648  Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases
Jie Yang, Donna McEachern, Wenyuan Li, Mary A. Davis, Huai Li, Meredith A. Morgan, Longchuan Bai, Jonathan T. Sebolt, Haiying Sun, Theodore S. Lawrence, Shaomeng Wang, and Yi Sun

658  Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor
Hiroyoshi Hattori, Ferdinandos Skoulidas, Paul Russell, and Ashok R. Venkitaraman

668  Rapamycin Reverses Splenomegaly and Inhibits Tumor Development in a Transgenic Model of Epstein-Barr Virus–Related Burkitt’s Lymphoma
Osman Cen and Richard Longnecker
MOLECULAR MEDICINE IN PRACTICE

Gene Expression Profiling Provides Insights into Pathways of Oxaliplatin-Related Sinusoidal Obstruction Syndrome in Humans
Laura Rubbia-Brandt, Sébastien Tauzin, Catherine Brezault, Céline Delucinge-Vivier, Patrick Descombes, Bertand Dousset, Pietro E. Majno, Gilles Mentha, and Benoit Terris

Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma

ABOUT THE COVER

Genetically-engineered mouse models often represent some of the most physiologically accurate models of cancer from which to understand the tumor microenvironment and with which to perform preclinical trials. Abraham and colleagues present studies of a prototypic insulin-like growth factor receptor inhibitor using both genetically-engineered mouse models and the shell-free quail chorioallantois membrane (CAM) assay. Remarkably, the inexpensive short term (2 week) CAM assay offers xenografted tumors a scaffold of lymphatics, arteries, and veins that mimic short-term in vivo growth with all the advantages of intravital imaging. Photograph credits, Elaine Huang and Audra Lee. For details, see article by Abraham and colleagues on page 697.